Contact Information: Contacts: MDRNA, Inc.: Peter Garcia Chief Financial Officer (425) 908-3634 pgarcia@mdrnainc.com Westwicke Partners (Investors): Stefan Loren, Ph.D. (443) 213-0507 sloren@westwicke.com John Woolford (443) 213-0506 john.woolford@westwicke.com McKinney|Chicago (Media): Alan Zachary (312) 944-6784 x 316 or (708) 707-6834 azachary@mckinneychicago.com
MDRNA, Inc. to Present at the 12th Annual BIO CEO & Investor Conference
Will Also Participate in a Panel Discussion on RNAi-Based Technology
| Source: MDRNA, Inc
BOTHELL, WA--(Marketwire - February 1, 2010) - MDRNA, Inc. (NASDAQ : MRNA ), a leading
RNAi-based drug discovery and development company, today announced that it
will present at the 12th Annual BIO CEO & Investor Conference being held at
the Waldorf Astoria Hotel in New York City, New York. J. Michael French,
MDRNA's President and Chief Executive Officer, will provide an overview of
the Company and its progress in key programs on Monday, February 8, 2010 at
1:00 p.m. (Eastern Time). Mr. French will also participate in a panel
discussion on RNAi-based technology at 3:00 p.m. (Eastern Time) at the
conference.
To access the live webcast of the MDRNA presentation, please visit the
Investors section of the Company's website at http://www.mdrnainc.com and
go to the Event Calendar or click on the following link:
http://www.veracast.com/webcasts/bio/ceoinvestor2010/48108103.cfm. Please
allow time prior to the presentation to register and download any necessary
software. A replay of the presentation will be available on the Investors
section of the MDRNA website under Event Calendar approximately one hour
after the live presentation and will be archived for three months. The
RNAi-based technology panel discussion will not be webcast.
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is the largest investor conference
focused on the biotechnology industry. The conference provides a forum for
public and private equity investors, research analysts, investment bankers
and senior-level industry executives to learn about and discuss investment
trends and investment opportunities in the biotechnology industry. For more
information, visit www.ceo.bio.org.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and
commercialization of therapeutic products based on RNA interference (RNAi).
Our goal is to improve human health through the development of RNAi-based
compounds and drug delivery technologies that together provide superior
therapeutic options for patients. Over the past decade, we have developed
substantial capabilities in molecular biology, cellular biology, lipid
chemistry, peptide chemistry, pharmacology and bioinformatics, which we are
applying to a wide range of RNAi technologies and delivery approaches.
These capabilities plus the in-licensing of key RNAi-related intellectual
property have rapidly enabled us to become a leading RNAi-based
therapeutics company with a pre-clinical pipeline in oncology. Through our
capabilities, expertise and know-how, we are incorporating multiple RNAi
technologies as well as peptide- and lipid-based delivery approaches into a
single integrated drug discovery platform that will be the engine for our
clinical pipeline as well as a versatile platform for establishing broad
therapeutic partnerships with biotechnology and pharmaceutical companies.
We are also investing in new technologies that we expect to lead to safer
and more effective RNAi-based therapeutics while aggressively building upon
our broad and extensive intellectual property estate. By combining broad
expertise in siRNA science with proven delivery platforms and a strong IP
position, MDRNA is well positioned as a leading RNAi-based drug discovery
and development company. Additional information about MDRNA, Inc. is
available at http://www.mdrnainc.com.
MDRNA Forward-Looking Statements
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of MDRNA to
obtain additional funding; (ii) the ability of MDRNA to attract and/or
maintain manufacturing, research, development and commercialization
partners; (iii) the ability of MDRNA and/or a partner to successfully
complete product research and development, including preclinical and
clinical studies and commercialization; (iv) the ability of MDRNA and/or a
partner to obtain required governmental approvals; and (v) the ability of
MDRNA and/or a partner to develop and commercialize products that can
compete favorably with those of competitors. Additional factors that could
cause actual results to differ materially from those projected or suggested
in any forward-looking statements are contained in MDRNA's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. MDRNA assumes no obligation to update
and supplement forward-looking statements because of subsequent events.